Scinai Immunotherapeutics (SCNI) versus Its Peers Head to Head Contrast

Scinai Immunotherapeutics (NASDAQ:SCNI) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Scinai Immunotherapeutics to related companies based on the strength of its earnings, risk, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Profitability

This table compares Scinai Immunotherapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Scinai Immunotherapeutics Competitors	-12,319.70%	-407.93%	-30.95%

Insider & Institutional Ownership

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for Scinai Immunotherapeutics and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1	0	0	0	1.00
Scinai Immunotherapeutics Competitors	9874	15295	45659	1600	2.54

As a group, “Biotechnology” companies have a potential upside of 126.22%. Given Scinai Immunotherapeutics’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Scinai Immunotherapeutics has less favorable growth aspects than its competitors.

Volatility & Risk

Scinai Immunotherapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics’ competitors have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Earnings and Valuation

This table compares Scinai Immunotherapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31 million	-$8.31 million	0.05
Scinai Immunotherapeutics Competitors	$700.38 million	$9.44 million	-18.76

Scinai Immunotherapeutics’ competitors have higher revenue and earnings than Scinai Immunotherapeutics. Scinai Immunotherapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Scinai Immunotherapeutics Company Profile

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects. Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.